Welcome to STN International! Enter x:x

LOGINID: SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * *
                     Welcome to STN International
                 Web Page for STN Seminar Schedule - N. America
NEWS
                 STN AnaVist, Version 1, to be discontinued
        APR 04
NEWS
NEWS
        APR 15
                 WPIDS, WPINDEX, and WPIX enhanced with new
                 predefined hit display formats
NEWS
        APR 28
                 EMBASE Controlled Term thesaurus enhanced
NEWS
      5
         APR 28
                 IMSRESEARCH reloaded with enhancements
NEWS
      6
        MAY 30
                 INPAFAMDB now available on STN for patent family
                 searching
NEWS
        MAY 30
                 DGENE, PCTGEN, and USGENE enhanced with new homology
                 sequence search option
        JUN 06
NEWS
     8
                 EPFULL enhanced with 260,000 English abstracts
NEWS
      9
         JUN 06
                 KOREAPAT updated with 41,000 documents
NEWS 10
         JUN 13
                 USPATFULL and USPAT2 updated with 11-character
                 patent numbers for U.S. applications
        JUN 19
NEWS 11
                 CAS REGISTRY includes selected substances from
                 web-based collections
NEWS 12
        JUN 25
                 CA/CAplus and USPAT databases updated with IPC
                 reclassification data
NEWS 13
         JUN 30
                 AEROSPACE enhanced with more than 1 million U.S.
                 patent records
NEWS 14
         JUN 30
                 EMBASE, EMBAL, and LEMBASE updated with additional
                 options to display authors and affiliated
                 organizations
NEWS 15
         JUN 30
                 STN on the Web enhanced with new STN AnaVist
                 Assistant and BLAST plug-in
NEWS 16
         JUN 30
                 STN AnaVist enhanced with database content from EPFULL
NEWS 17
         JUL 28
                 CA/CAplus patent coverage enhanced
NEWS 18
        JUL 28
                 EPFULL enhanced with additional legal status
                 information from the epoline Register
NEWS 19
         JUL 28
                 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20
        JUL 28
                 STN Viewer performance improved
        AUG 01
NEWS 21
                 INPADOCDB and INPAFAMDB coverage enhanced
        AUG 13
NEWS 22
                 CA/CAplus enhanced with printed Chemical Abstracts
                 page images from 1967-1998
NEWS 23
         AUG 15
                 CAOLD to be discontinued on December 31, 2008
NEWS 24
         AUG 15
                 CAplus currency for Korean patents enhanced
NEWS 25
        AUG 25
                 CA/CAplus, CASREACT, and IFI and USPAT databases
                 enhanced for more flexible patent number searching
NEWS 26
        AUG 27
                 CAS definition of basic patents expanded to ensure
                 comprehensive access to substance and sequence
                 information
```

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:52:59 ON 08 SEP 2008

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:53:08 ON 08 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2008 HIGHEST RN 1047406-12-1 DICTIONARY FILE UPDATES: 7 SEP 2008 HIGHEST RN 1047406-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\STNEXP\Queries\10596745s3.str





chain nodes :
7 8 9 10 12 13 14 16 17

ring nodes : 1 2 3 4 5 6 chain bonds :

2-7 5-8 8-9 9-10 10-12 12-13 13-14 13-16 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-7 9-10 10-12 12-13 13-14 13-16 16-17

exact bonds : 5-8 8-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,N

G2:C,O,N

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom 12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:Atom

L1 STRUCTURE UPLOADED

 \Rightarrow s 11 sss sam

SAMPLE SEARCH INITIATED 08:53:35 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 108 TO ITERATE

100.0% PROCESSED 108 ITERATIONS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE** BATCH **COMPLETE** 9 ANSWERS

PROJECTED ITERATIONS: 1537 TO 2783 PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1

=> d scan

L2 9 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-ethyl-1Hpyrazol-3-yl)-

MF C18 H17 N7 O

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.92 1.13

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:54:16 ON 08 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2008 VOL 149 ISS 11 FILE LAST UPDATED: 7 Sep 2008 (20080907/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 12

L3 1 L2

=> file reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 0.48 1.61

FILE 'REGISTRY' ENTERED AT 08:54:34 ON 08 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2008 HIGHEST RN 1047406-12-1 DICTIONARY FILE UPDATES: 7 SEP 2008 HIGHEST RN 1047406-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l1 sss full

FULL SEARCH INITIATED 08:54:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1944 TO ITERATE

100.0% PROCESSED 1944 ITERATIONS 172 ANSWERS

SEARCH TIME: 00.00.01

L4 172 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.36 179.97

FILE 'CAPLUS' ENTERED AT 08:54:47 ON 08 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2008 VOL 149 ISS 11 FILE LAST UPDATED: 7 Sep 2008 (20080907/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 14

3 L4 L5

=> d ibib abs hitstr 1-3

ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:790854 CAPLUS

DOCUMENT NUMBER: 145:230644

TITLE: Preparation of pyrimidine derivatives and their use as

Tie2 receptor tyrosine kinase inhibitors

INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur;

Mccoull, William

Astrazeneca AB, Swed.; Astrazeneca Uk Limited PATENT ASSIGNEE(S):

PCT Int. Appl., 168pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA:	FENT	NO.			KIND DATE				APPLICATION NO.						DATE			
WO	WO 2006082373					A1 20060810			WO 2006-GB284						20060127			
	W:	ΑE,	AG,	ΑL,	ΑM,	ΑT,	ΑU,	ΑZ,	BΑ,	BB,	ВG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,	
		GE,	GH,	GM,	HR,	ΗU,	ID,	ΙL,	IN,	IS,	JΡ,	ΚE,	KG,	KM,	ΚN,	KP,	KR,	
		KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	
		MZ,	ΝA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	
		SG,	SK,	SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	
		VN,	YU,	ZA,	ZM,	ZW												
	RW:	AT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	IE,	
		IS,	ΙΤ,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG,	BW,	GH,	
		GM,	KE,	LS,	MW,	MΖ,	NΑ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
		KG,	KΖ,	MD,	RU,	ТJ,	TM											
EP	EP 1863805				A1 20071212				EP 2006-701245						20060127			
	R:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	IE,	
		IS,	ΙT,	LI,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR		
JP	JP 2008528663						T 20080731 JP 2007-553683								20060127			
IN	IN 2007DN05604						A 20070817 IN 2007-DN5604								20070719			
CN	CN 101137652						20080305 CN 2006-80007855							20070911				
RIORIT	ORITY APPLN. INFO.:									GB 2	005-	1984			A 2	0050	201	
										GB 2	005-	2417		i	A 2	0050	205	
										GB 2	005-	1261	4	2	A 2	0050	621	
										WO 2	006-	GB28	4	1	₩ 2	0060	127	
THER SO	HER SOURCE(S):						145:	2306	44									

SOURCE (S): 45:2306

GΙ

$$c\equiv c$$
 NH_2
 NH_2
 $NH-CO-NH-CH_2$
 NH_2

AΒ Substituted pyrimidine derivs. I, wherein R1 is an (un)substituted amine, (un) substituted 3-7 membered heterocyclic ring; R2 and R3 are H, (un) substituted alkyl, (un) substituted alkoxy; A is a 5 or 6 membered heteroaryl ring; R4 is halo, cyano, alkoxy, cyclopropyl, alkyl, where the alkoxy or alkyl groups are optionally substituted by cyano or 1 or more fluoro groups; L is meta or para attached by an (un)substituted amide, (un) substituted amine, alkyl group; B is a cycloalkyl, heterocyclic ring, aryl, heteroaryl, bicyclic ring; R5 is a halo, hydroxyl, amino, alkylamino, cyano, cycloalkyl ring, an (un)substituted 3 to 7 membered heterocyclic ring; m and n are 0-3 are prepared and used as as medicaments and in the production of an anti-angiogenic effect in a warm blooded animal. Thus, II was prepared and tested as an in vitro inhibitor of the Tie2 receptor tyrosine kinase and in the inhibition of autophosphorylation of Tie2 receptor tyrosine kinase (IC50 are 1.5 and 1.9 μM resp.). Further, I can be used in the treatment of cancer and as antineoplastic prodrugs.

IT 857265-17-9P, Phenyl[3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857266-46-7P, Phenyl 3-[[2-[[3-(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenylcarbamate 905439-39-6P 905439-44-3P 905439-48-7P 905439-61-4P 905439-64-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. and their use as Tie2 receptor tyrosine kinase inhibitors)

RN 857265-17-9 CAPLUS

CN Carbamic acid, [3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)

RN 857266-46-7 CAPLUS

CN Carbamic acid, [3-[[2-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)

RN 905439-39-6 CAPLUS

CN Carbamic acid, [5-[(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-, phenyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} c & c \\ \hline N & NH_2 \\ \hline NH-C-OPh \\ \hline 0 \\ \end{array}$$

RN 905439-44-3 CAPLUS

CN Carbamic acid, [4-methyl-3-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 905439-48-7 CAPLUS

CN Carbamic acid, [6-methyl-5-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl]-, phenyl ester (9CI) (CA INDEX NAME)

RN 905439-61-4 CAPLUS

CN Carbamic acid, [5-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]-3-pyridinyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

RN 905439-64-7 CAPLUS

CN Carbamic acid, [5-[[2-[[3-(4-morpholiny1)propy1]amino]-5-pyrimidiny1]ethyny1]-3-pyridiny1]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:381241 CAPLUS

DOCUMENT NUMBER: 144:432828

TITLE: Heteroaryl-substituted alkyne compounds as protein

kinase inhibitors, their preparation, pharmaceutical

compositions, and use in therapy

INVENTOR(S): Chaffee, Stuart C.; Albrecht, Brian K.; Hodous, Brian

L.; Martin, Matthew W.; McGowan, David C.; Dimauro, Erin F.; Reddy, Gade; Cee, Victor J.; Olivieri, Philip

R.; Reed, Anthony; Romero, Karina

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 330 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

GΙ

```
PATENT NO.
                   KIND DATE APPLICATION NO. DATE
                        ----
                                            _____
                                                                   _____
     _____
                    A2 20060427 WO 2005-US37299
     WO 2006044823
                                                                   20051017
     WO 2006044823
                         A3 20060615
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
             NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
             SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
             YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     US 20060217380
                    A1
                                20060928
                                           US 2005-251490
                                                                    20051014
     AU 2005295414
                         Α1
                                20060427
                                          AU 2005-295414
                                                                    20051017
                               20060427 CA 2005-2583907
20070704 EP 2005-812237
     CA 2583907
                         A1
                                                                    20051017
     EP 1802586
                         A2
                                                                    20051017
         R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
             BA, HR, MK, YU
                                            US 2004-620100P P 20041018
US 2005-251490 A 20051014
WO 2005-US37299 W 20051017
PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 144:432828
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AΒ The invention relates to heteroaryl-substituted alkynes of formula I, which are protein kinase modulators. In compds. I, W, X, Y, and Z are independently selected from N and (un)substituted C; R1 is (un)substituted amino, acyl, acyloxy, carboxylate, carbamoyl, thiocarbamoyl, etc.; and R2 is 5- to 8-membered monocyclic, 6- to 12-membered bicyclic, or 7- to 14-membered tricyclic ring system, optionally including 1-3 heteroatoms selected from O, N, and S; including stereoisomers, tautomers, solvates, salts, derivs., and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the prophylaxis and treatment of protein kinase-mediated diseases, including inflammation, cancer and related conditions. Chlorination of 3-iodo-4-methylbenzoic acid and amidation with 3-trifluoromethylaniline gave benzamide II, which underwent coupling with 2-amino-5ethynylpyrimidine (preparation from 2-amino-5-iodopyrimidine and trimethylsilylacetylene is given) to give pyrimidinylalkyne III. Several compds. of the invention, e.g., III, express IC50 values of less than or equal to 10 μM both for Tie-2 and Lck kinase.
- IT 884602-98-6P, N-[4-[2-(2-Aminopyrimidin-5-yl)ethynyl]-3methylphenyl]-N'-[3-(trifluoromethyl)phenyl]urea 884603-00-3P
 884604-13-1P, N-[3-Methyl-4-[[4-[[2-(methyloxy)phenyl]oxy]-2-[[4(4-methyl-1-piperazinyl)phenyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[3(trifluoromethyl)phenyl]urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of heteroaryl-substituted alkynes as protein kinase modulators)

RN 884602-98-6 CAPLUS

CN Urea, N-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-methylphenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{NH-C-NH} \\ \text{CF3} \end{array}$$

RN 884603-00-3 CAPLUS

CN Urea, N-[4-[2-(2-amino-5-pyrimidiny1)ethyny1]-3-methylpheny1]-N'-(3-fluoropheny1)- (CA INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{N} \\ \text{N} \end{array}$$

RN 884604-13-1 CAPLUS

CN Urea, N-[4-[2-[4-(2-methoxyphenoxy)-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-pyrimidinyl]ethynyl]-3-methylphenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

Me

ACCESSION NUMBER: 2005:588668 CAPLUS

DOCUMENT NUMBER: 143:115557

TITLE: Preparation of 2-aminopyrimidine derivatives as

inhibitors of Tie2 receptor tyrosine kinases

INVENTOR(S): Jones, Clifford David; Luke, Richard William Arthur;

McCoull, William

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 178 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

P	PATENT NO.						KIND DATE				APPL	ICAT	ION I	DATE				
W	0	2005060970				A1 20050707			WO 2004-GB5337					20041220				
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BΑ,	BB,	ВG,	BR,	BW,	BY,	BZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DΖ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
			NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			ТJ,	TM,	TN,	TR,	TT,	ΤZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	ΚE,	LS,	M₩,	ΜZ,	NA,	SD,	SL,	SZ,	ΤZ,	UG,	ZM,	ZW,	AM,
			ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	ΒE,	BG,	CH,	CY,	CZ,	DE,	DK,
			EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IS,	ΙΤ,	LT,	LU,	MC,	NL,	PL,	PT,
			RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,
			MR,	ΝE,	SN,	TD,	ΤG											
E	Ρ	1737463			A1 20070103				EP 2004-806139					20041220				
		R:	ΑT,	ΒE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,
			IS,	ΙΤ,	LI,	LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR		
_	CN 1917879					A								20041220				
										JP 2006-546306								
_										US 2006-596745								
I	IN 2006MN00846					A 20070608			IN 2006-MN846									
PRIORI	RIORITY APPLN. INFO.:										GB 2003-30000							
											GB 2004-16849					A 20040729		
		~-									WO 2	004-	GB53.	37	1	₩ 2	0041	220

OTHER SOURCE(S): MARPAT 143:115557

$$R^3$$
 $C \equiv C$
 R^4
 $(R^5)_n$
 $(R^6)_m$
 R^6

AB Title compds. I [wherein R1, R2 = H, alkyl, alkanoyl; R3, R4 = H, alkyl, alkoxy; R5 = cyclopropyl, halo, cyano; m, n = 0-3; R6 = halo, oxo, cyano; etc., or salts thereof] were prepared as inhibitors of Tie2 receptor

tyrosine kinases. Processes for the synthesis of I and some intermediates involved are claimed. For example, 2-amino-5-iodopyrimidine underwent Pd-catalyzed coupling with 3-ethynylaniline in the presence of CuI. The resultant substituted aniline was condensed with a carbamate, which was obtained from Ph chloroformate and 5-amino-3-methylisoxazole, to give urea II. This compound showed inhibition against Tie2 receptor tyrosine kinase in vitro and inhibition of autophosphorylation of Tie2 receptor tyrosine kinase with IC50 values of 19.871 μM and 0.337 μM , resp. Therefore, I and their pharmaceutical compns. have potential use in the production of an anti-angiogenic effect in a warm-blooded animal.

IT 857265-16-8P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5tert-butylisoxazol-3-yl)urea 857265-17-9P, Phenyl
[3-[(2-aminopyrimidin-5-yl)ethynyl]phenyl]carbamate 857265-31-7P
, N-[3-[[2-[(2-Aminoethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857265-32-8P, N-[3-[[2-[(3-Aminopropyl)amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-46-7P, Phenyl [3-[[2-[[3-(dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]carbamate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)

(inhibitor; preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN 857265-16-8 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

RN 857265-17-9 CAPLUS

CN Carbamic acid, [3-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)

RN 857265-31-7 CAPLUS

CN Urea, N-[3-[2-[2-[(2-aminoethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

RN 857265-32-8 CAPLUS

CN Urea, N-[3-[2-[(3-aminopropyl)amino]-5-pyrimidinyl]ethynyl]phenyl]-N'[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

RN 857266-46-7 CAPLUS

CN Carbamic acid, [3-[[2-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)

ΙT 857264-91-6P, N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-[2fluoro-5-(trifluoromethyl)phenyl]urea 857264-93-8P, N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]urea 857264-94-9P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]urea 857264-95-0P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2fluorophenyl)urea 857264-96-1P, N-[3-[(2-Aminopyrimidin-5yl)ethynyl]phenyl]-N'-(3-fluorophenyl)urea 857264-97-2P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4-fluorophenyl)urea 857264-98-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-yl)ethynyl]phenyl]-N'-(3-yl)ethynylmethoxyphenyl)urea 857264-99-4P, N-[3-[(2-Aminopyrimidin-5y1)ethynyl]phenyl]-N'-(2,5-difluorophenyl)urea 857265-00-0P,N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-(1,3-benzodioxol-5-y1)urea857265-01-1P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-[3-(trifluoromethyl) phenyl]urea 857265-02-2P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-methoxyphenyl)urea 857265-03-3P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(4methoxyphenyl)urea 857265-04-4P, N-[3-[(2-Aminopyrimidin-5y1) ethynyl]phenyl]-N'-(3,4-difluorophenyl)urea 857265-05-5P, N-[3-[(2-Aminopyrimidin-5-y1)ethyny1]pheny1]-N'-(3-cyanopheny1)urea857265-06-6P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3chlorophenyl)urea 857265-07-7P, N-[3-[(2-Aminopyrimidin-5yl)ethynyl]phenyl]-N'-cyclopentylurea 857265-08-8P, N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-(3,5-difluorophenyl)urea857265-09-9P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5tert-butyl-1, 3, 4-thiadiazol-2-yl) urea 857265-13-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(3-methylisoxazol-5yl)urea 857265-14-6P, N-[3-[[[[3-[(2-Aminopyrimidin-5yl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]acetamide 857265-15-7P, N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857265-18-0P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(2-oxopiperidin-3-yl)urea 857265-19-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-(methylamino)pyrimidin-5-yl]ethynyl]phenyl]urea 857265-22-6P, N-(5-tert-Butylisoxazol-3-y1)-N'-[3-[[2-(dimethylamino)pyrimidin-5yl]ethynyl]phenyl]urea 857265-23-7P, N-(5-tert-Butylisoxazol-3y1)-N'-[3-[[2-[[2-(morpholin-4-y1)ethy1]amino]pyrimidin-5yl]ethynyl]phenyl]urea 857265-24-8P, N-(5-tert-Butylisoxazol-3-

```
y1)-N'-[3-[[2-[[3-(morpholin-4-y1)propy1]amino]pyrimidin-5-
yl]ethynyl]phenyl]urea 857265-25-9P, N-(5-tert-Butylisoxazol-3-
y1)-N'-[3-[[2-[(2-methoxyethy1)amino]pyrimidin-5-y1]ethyny1]pheny1]urea
857265-26-0P, N-(5-tert-Butylisoxazol-3-y1)-N'-[3-[[2-[[3-(1H-
imidazol-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857265-27-1P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(3-vat)-3-yl)-N'-]]
methoxypropyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857265-28-2P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[(2-1)^2]]]
hydroxyethyl)amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-29-3P
, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(pyrrolidin-1-
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-30-6P,
N-(5-\text{tert-Butylisoxazol}-3-y1)-N'-[3-[[2-[[3-(pyrrolidin}-1-
y1)propyl]amino]pyrimidin-5-y1]ethynyl]phenyl]urea 857265-33-9P,
N-(5-\text{tert-Butylisoxazol-}3-y1)-N'-[3-[[2-[[2-(dimethylamino)ethyl]amino]pyr]
imidin-5-yl]ethynyl]phenyl]urea 857265-34-0P,
N-(5-\text{tert-Butylisoxazol-}3-y1)-N'-[3-[[2-[[3-(dimethylamino)propy1]amino]py]]
rimidin-5-yl]ethynyl]phenyl]urea 857265-35-1P,
N-[5-[[3-[[(5-tert-Butylisoxazol-3-yl)amino]carbonyl]amino]phenyl]ethynyl
]pyrimidin-2-y1]glycinamide 857265-36-2P 857265-37-3P,
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(1H-imidazol-4-yl)]]]]
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-38-4P,
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(pyridin-2-1)]]]]
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-39-5P,
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[3-(isopropylamino)propyl]amino]p
yrimidin-5-yl]ethynyl]phenyl]urea 857265-40-8P,
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[3-(4-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1-methylpiperazin-1
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-41-9P,
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(pyridin-4-)]]]]
y1)ethy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857265-42-0P,
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-43-1P,
N-(5-Methylisoxazol-3-yl)-N'-[3-[[2-[[2-(pyrrolidin-1-)]]])
y1)ethy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857265-47-5P,
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-48-6P,
N-(3-Methylisothiazol-5-yl)-N'-[3-[[2-[[2-(pyrrolidin-1-
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-49-7P,
N-(3-Fluoropheny1)-N'-[3-[[2-[[2-(pyrrolidin-1-y1)ethy1]amino]pyrimidin-5-
yl]ethynyl]phenyl]urea 857265-50-0P, N-(4-Methoxyphenyl)-N'-[3-
[[2-[[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857265-51-1P, N-(2-Fluorophenyl)-N'-[3-[[2-[[2-(pyrrolidin-1-
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-52-2P,
N-(2,5-Difluorophenyl)-N'-[3-[[2-[[2-(pyrrolidin-1-
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-53-3P,
N-(3,4-Difluorophenyl)-N'-[3-[[2-[[2-(pyrrolidin-1-
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-54-4P,
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[[2-[[2-(pyrrolidin-1-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ingle-ing
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-55-5P,
N-[3-[[2-[[2-(Pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-
N'-[4-(trifluoromethyl)phenyl]urea 857265-56-6P,
N-(1,3-Benzodioxol-5-yl)-N'-[3-[[2-[[2-(pyrrolidin-1-
y1)ethy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857265-57-7P,
N-(4-Fluoropheny1)-N'-[3-[[2-[[2-(pyrrolidin-1-y1)ethy1]amino]pyrimidin-5-
yl]ethynyl]phenyl]urea 857265-58-8P, N-(3-Chlorophenyl)-N'-[3-
[[2-[[2-(pyrrolidin-1-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857265-59-9P, N-(5-Methylisoxazol-3-yl)-N'-[3-[[2-[[2-(morpholin-4-
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-60-2P,
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-61-3P,
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[[2-[[2-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(m
y1)ethy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857265-62-4P,
N-(5-Methylisoxazol-3-yl)-N'-[3-[[2-[[3-(morpholin-4-
```

```
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-63-5P,
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[[2-[[3-(morpholin-4-indiazol-2-yl)]]]
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-64-6P,
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[[2-[[3-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(morpholin-4-(m
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-65-7P,
N-(5-Methylisoxazol-3-yl)-N'-[4-[[2-[[2-(pyrrolidin-1-
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-68-0P,
N-(5-\text{tert-Butylisoxazol}-3-y1)-N'-[4-[[2-[[2-(pyrrolidin}-1-
y1)ethy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857265-69-1P,
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857265-70-4P,
N-[2-Fluoro-5-(trifluoromethyl)phenyl]-N'-[4-[[2-[[2-(pyrrolidin-1-
y1)ethy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857265-71-5P,
N-[5-[[3-[[(5-tert-Butylisoxazol-3-yl)amino]carbonyl]amino]phenyl]ethynyl
]pyrimidin-2-yl]-2-(2-methoxyethoxy)acetamide 857265-72-6P,
N-[6-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-2-yl]-N'-(5-tert-
butylisoxazol-3-yl)urea 857265-76-0P, N-[2-[(2-Aminopyrimidin-5-
yl)ethynyl]pyridin-4-yl]-N'-(5-tert-butylisoxazol-3-yl)urea
857265-78-2P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-
y1]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea 857265-80-6P,
N-[5-[(2-Aminopyrimidin-5-y1)ethyny1]-1,3,4-thiadiazol-2-y1]-N'-[2-fluoro-
5-(trifluoromethyl)phenyl]urea 857265-82-8P,
N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(5-tert-1)
butylisoxazol-3-y1)urea 857265-84-0P, N-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857265-85-1P,
2-Phenyl-N-[3-[2-(2-aminopyrimidin-5-yl)ethynyl]phenyl]acetamide
857265-86-2P, N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-2-(3-
methoxyphenyl)acetamide 857265-87-3P, N-[3-[(2-Aminopyrimidin-5-
y1)ethynyl]phenyl]-2-[3-(trifluoromethyl)phenyl]acetamide
857265-88-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-[4-
(trifluoromethyl)phenyl]acetamide 857265-89-5P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-2-(3-methylisoxazol-5-
yl)acetamide 857265-91-9P, N-[4-[(2-Aminopyrimidin-5-
y1)ethynyl]phenyl]-2-(2-methoxyphenyl)acetamide 857265-92-0P,
yl)acetamide 857265-93-1P, N-[3-[(2-Aminopyrimidin-5-
y1)ethynyl]phenyl]-N'-(2,2-dimethyltetrahydro-2H-pyran-4-y1)urea
857265-94-2P, N-[6-[(2-Aminopyrimidin-5-yl)ethynyl]pyrimidin-4-yl]-
N'-(5-tert-butylisoxazol-3-yl)urea 857265-96-4P,
N'-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N-(5-tert-butylisoxazol-3-
yl)-N-methylurea 857265-97-5P, N-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-N'-phenylurea 857265-98-6P,
cyclopropyl-1H-pyrazol-5-yl)urea 857265-99-7P,
N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-1)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-1)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-1)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-1)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-1)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-1)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-1)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-1)ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]ethyll[n]et
2-y1)urea 857266-00-3P, N-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)urea
857266-01-4P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(5-yl)ethynyl]phenyl]-N'-(5-yl)ethynyl
isopropyl-1, 3, 4-thiadiazol-2-yl) urea 857266-02-5P,
N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-(4-tert-butyl-1,3-thiazol-
2-yl)urea 857266-03-6P, N-[3-[(2-Aminopyrimidin-5-
v1) ethynv1] phenv1] -N'-(5-methylisoxazol-3-v1) urea 857266-04-7P,
N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-[5-(trifluoromethyl)-1,3,4-
thiadiazol-2-yl]urea 857266-05-8P, N'-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-N-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-
yl]urea 857266-06-9P, N-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-N'-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)urea
857266-07-0P, N-Phenyl-N'-[3-[[2-[[3-(piperidin-1-
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-09-2P,
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-10-5P,
N-[3-[[2-[[3-(Piperidin-1-y1)propy1]amino]pyrimidin-5-y1]ethyny1]pheny1]-
```

```
N'-[4-(trifluoromethyl)pyridin-2-yl]urea 857266-11-6P,
N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-N'-[3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[2-[[3-(piperidin-1-yl)-N'-1]3-[[3-[[3-(piperidin-1-yl)-N'-1]3-[[3-[[3-(piperidin-1-yl)-N'-1]3-[[3-[[3-(piperidin-1-yl)-N'-1]3-[[3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3-[[3-(piperidin-1-yl)-N'-1]3
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-12-7P,
N-(3-Methylisoxazol-5-yl)-N'-[3-[[2-[[3-(piperidin-1-1)]]]]
y1)propy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857266-13-8P,
N-(2-Methoxypheny1)-N'-[3-[[2-[[3-(piperidin-1-y1)propy1]amino]pyrimidin-5-
yl]ethynyl]phenyl]urea 857266-14-9P, N-(3-Fluorophenyl)-N'-[3-
[[2-[[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-15-0P, N-[3-[[2-[(4-Aminobuty1)amino]pyrimidin-5-
yl]ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-yl)urea 857266-16-1P
, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(piperidin-1-yl)]]]]
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-17-2P,
N-(5-\text{tert-Butylisoxazol-}3-\text{yl})-N'-[3-[[2-[[2-(isopropylamino)ethyl]amino]py]
rimidin-5-yl]ethynyl]phenyl]urea 857266-18-3P,
hydroxyethoxy)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-19-4P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[4-
(dimethylamino)butyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-20-7P, N-(5-tert-Butylisoxazol-3-y1)-N'-[3-[[2-[[2-
(dimethylamino)-1-methylethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-21-8P, N-(5-tert-Butylisoxazol-3-y1)-N'-[3-[[2-[[1-methyl-2-
(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-22-9P 857266-25-2P 857266-26-3P,
N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-[[2-(piperazin-1-yl)-N'-[3-[[2-[[2-(piperazin-1-yl)-N'-[3-[[2-[[2-[yiperazin-1-yl)-N'-[3-[[2-[[2-[yiperazin-1-yl)-N'-[3-[[2-[yiperazin-1-yl)-N'-[3-[[2-[yiperazin-1-yl)-N'-[3-[[2-[yiperazin-1-yl)-N'-[3-[yiperazin-1-yl)-N'-[3-[yiperazin-1-yl)-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[3-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yiperazin-1-yl]-N'-[yi
y1)ethy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857266-27-4P,
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-29-6P,
y1)ethy1]amino]pyrimidin-5-y1]ethyny1]pheny1]urea 857266-32-1P,
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-[3-[[2-[[3-(morpholin-4-in-methyl-N'-[3-[[2-[[3-(morpholin-4-in-methyl-N'-[3-[[2-[[3-(morpholin-4-in-methyl-N'-[3-[[2-[[3-(morpholin-4-in-methyl-N'-[3-[[3-[[3-(morpholin-4-in-methyl-N'-[3-[[3-[[3-[in-methyl-N'-[3-[in-methyl-N'-[3-[in-methyl-N'-[3-[in-methyl-N'-[3-[in-methyl-N'-[3-[in-methyl-N'-[3-[in-methyl-N'-[3-[in-methyl-N'-]]]]]]]])])])])
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-33-2P,
N-(5-tert-Butylisoxazol-3-yl)-N-methyl-N'-[3-[[2-[[3-(piperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-1-iperidin-
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-34-3P,
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[[3-(piperidin-1-methyl-1H-pyrazol-5-yl)]]]
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-36-5P,
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[[3-(morpholin-4-in-methyl-1H-pyrazol-5-yl)]]]
yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-37-6P,
N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-[[2-(morpholin-4-in-methyl-1H-pyrazol-5-yl)]]]
yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea 857266-38-7P,
(\verb|dimethylamino|| ethyl|| amino|| pyrimidin-5-yl|| ethynyl|| phenyl|| urea
857266-39-8P, N-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-tert-Butyl-1-methyl-1H-pyrazol-5-yl)]
[[2-(isopropylamino)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-40-1P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-
\hbox{\tt [[3-(piperidin-1-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea}\\
[[3-(morpholin-4-yl)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-43-4P, N-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[[2-
[[2-(morpholin-4-yl)ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-44-5P, N-(5-tert-Butylisoxazol-3-y1)-N'-[3-[[2-[[2-[(2-
hydroxy-1-oxoethyl)amino]ethyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-45-6P, N-(5-tert-Butylisoxazol-3-y1)-N'-[3-[[2-[[3-[(2-
hydroxyethyl)amino]propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea
857266-48-9P, N-[3-[[2-[[3-(Dimethylamino)propyl]amino]pyrimidin-5-
yl]ethynyl]phenyl]-N'-phenylurea 857266-49-0P,
N-[3-[[2-[[3-(Dimethylamino)propyl]amino]pyrimidin-5-yl]ethynyl]phenyl]-N'-
(5-methylisoxazol-3-y1)urea~857266-50-3P, N-(5-tert-
Butylisoxazol-3-y1)-N'-[3-[[2-[[3-(dimethylamino)propy1]amino]pyrimidin-5-
yl]ethynyl]phenyl]-N-methylurea 857266-51-4P,
N'-[4-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N-(5-tert-butylisoxazol-3-
y1)-N-methylurea 857266-53-6P, N-[3-[(2-Aminopyrimidin-5-
y1)ethynyl]phenyl]-N'-(5-tert-butylisoxazol-3-y1)-N-methylurea
```

```
857266-57-0P, N-[5-[(2-Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-
N'-(5-tert-butylisoxazol-3-yl)urea 857266-61-6P,
methyl-1H-pyrazol-5-yl)urea 857266-63-8P, N-[5-[(2-
Aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-N'-(3-cyclopropyl-1-methyl-1H-
pyrazol-5-yl)urea 857266-64-9P, N-[5-[(2-Aminopyrimidin-5-
y1) ethyny1]-1,3-thiazol-2-y1]-N'-phenylurea 857266-65-0P,
N-[5-[(2-Aminopyrimidin-5-y1)ethyny1]-1,3-thiazol-2-y1]-N'-(2,2-y1)
dimethyltetrahydro-2H-pyran-4-yl)urea 857266-67-2P,
N-[5-[(2-Aminopyrimidin-5-y1)ethyny1]-1,3-thiazo1-2-y1]-N'-(3-cyclopropyl-
1-methyl-1H-pyrazol-5-yl)urea 857266-70-7P, N-[5-[(2-1)]2-1]2-1
Aminopyrimidin-5-yl)ethynyl]-1,3-thiazol-2-yl]-N'-(3-tert-butyl-1-methyl-
1H-pyrazol-5-yl)urea 857266-74-1P, N-[5-[(2-Aminopyrimidin-5-
yl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-phenylurea 857266-78-5P,
N-[5-[(2-Aminopyrimidin-5-y1)ethyny1]-1,3,4-thiadiazol-2-y1]-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-(2,2-y1)-N'-
dimethyltetrahydro-2H-pyran-4-yl)urea 857266-82-1P,
N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-
yl)urea 857266-84-3P, N-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-N'-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]urea
857266-86-5P, N-[3-[(2-Aminopyrimidin-5-y1)ethyny1]pheny1]-N'-(3-
cyclopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-88-7P,
N-[3-[(2-Aminopyrimidin-5-y1)ethyny1]pheny1]-N'-(3-tert-buty1-1-methy1-1H-1)ethy1-1H-1
pyrazol-5-yl)urea 857266-90-1P, N-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-N'-(1-tert-butyl-1H-pyrazol-4-yl)urea
857266-93-4P, N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-(3-
isopropyl-1-methyl-1H-pyrazol-5-yl)urea 857266-96-7P,
N-[3-[(2-Aminopyrimidin-5-y1)ethynyl]phenyl]-N'-(5-isopropyl-1,3,4-isopropyl-1)
oxadiazol-2-yl)urea 857266-99-0P, N-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-N'-(1-ethyl-1H-pyrazol-3-yl)urea 857267-02-8P
, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]phenyl]-N'-(1-isopropyl-1H-pyrazol-
3-yl)urea 857267-06-2P, N-[3-[(2-Aminopyrimidin-5-
yl)ethynyl]phenyl]-N'-[3-fluoro-5-(4-methylpiperazin-1-yl)phenyl]urea
857267-09-5P, N-[3-[(2-Aminopyrimidin-5-yl)ethynyl]-4-
methylphenyl]-N'-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (inhibitor; preparation of pyrimidine derivs. as inhibitors of Tie2 receptor
     tyrosine kinases)
857264-91-6 CAPLUS
Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-[2-fluoro-5-
(trifluoromethyl)phenyl]- (CA INDEX NAME)
```

$$H_2N$$
 N
 C
 C
 NH
 C
 NH
 C
 NH
 C

RN

CN

RN 857264-93-8 CAPLUS
CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 857264-94-9 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 857264-95-0 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-fluorophenyl)-(CA INDEX NAME)

$$H_2N$$
 N C C NH C NH

RN 857264-96-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-fluorophenyl)-(CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & &$$

RN 857264-97-2 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(4-fluorophenyl)-(CA INDEX NAME)

$$H_2N$$
 N C C NH C NH

RN 857264-98-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-(3-methoxypheny1)-(CA INDEX NAME)

RN 857264-99-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-(2,5-difluoropheny1)- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 857265-00-0 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-1,3-benzodioxol-5-yl- (CA INDEX NAME)

RN 857265-01-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 857265-02-2 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-(2-methoxypheny1)-(CA INDEX NAME)

RN 857265-03-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-(4-methoxypheny1)-(CA INDEX NAME)

$$H_2N$$
 N $C \equiv C$ NH C NH

RN 857265-04-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-(3,4-difluoropheny1)- (CA INDEX NAME)

RN 857265-05-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-cyanophenyl)- (CA INDEX NAME)

$$C = C$$
 $NH - C - NH$
 CN

RN 857265-06-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-chlorophenyl)- (CA INDEX NAME)

$$C = C - NH - C - NH$$

RN 857265-07-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-cyclopentyl- (CA INDEX NAME)

RN 857265-08-8 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3,5-difluorophenyl)- (CA INDEX NAME)

RN 857265-09-9 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)

RN 857265-13-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)

RN 857265-14-6 CAPLUS

CN Acetamide, N-[3-[[[[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)

RN 857265-15-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)

RN 857265-18-0 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(2-oxo-3-piperidinyl)- (CA INDEX NAME)

RN 857265-19-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-(methylamino)-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-22-6 CAPLUS

CN Urea, N-[3-[2-[2-(dimethylamino)-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

RN 857265-23-7 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-24-8 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-25-9 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(2-methoxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-26-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$C = C$$
 $NH-C-NH$
 $NH-C-N$

RN 857265-27-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(3-methoxypropyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-28-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(2-hydroxyethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-29-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} N & \text{NH-C-NH} \\ \hline \\ C & \text{NH-CH}_2\text{-CH}_2\text{-NH} \\ \hline \\ \text{t-Bu} \end{array}$$

RN 857265-30-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[3-(1-pyrrolidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-33-9 CAPLUS

CN Urea, N-[3-[2-[2-[[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

RN 857265-34-0 CAPLUS

CN Urea, N-[3-[2-[3-(dimethylamino)propyl]amino]-5pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA
INDEX NAME)

RN 857265-35-1 CAPLUS

CN Acetamide, 2-[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

RN

857265-36-2 CAPLUS Propanamide, 3-[[5-[2-[3-[[[[5-(1,1-dimethylethyl)-3-CN isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)

857265-37-3 CAPLUS RN

Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-(1H-imidazol-isoxazolyl)]]CN 5-yl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 857265-38-4 CAPLUS

CN pyridinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-39-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[3-[(1-methylethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-40-8 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

PAGE 1-A

$$\begin{array}{c|c} & & & \\ &$$

PAGE 1-B

__ Me

RN 857265-41-9 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[2-(4-pyridinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-42-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$C = C$$
 $NH = C = NH$
 $C = NH = CH_2)_3 = NH$
 $C = RH$

RN 857265-43-1 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} N & C & C \\ \hline O & NH-C-NH \\ \hline O & NH-CH_2-CH_2-N \\ \hline Me & NH-CH_2-CH_2-N \\ \hline \end{array}$$

RN 857265-47-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$N$$
 $NH-C-NH$
 S
 O
 $NH-CH_2-CH_2$
 N
 $NH-CH_2-CH_2$

RN 857265-48-6 CAPLUS

CN Urea, N-(3-methyl-5-isothiazolyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-49-7 CAPLUS

CN Urea, N-(3-fluorophenyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-50-0 CAPLUS

CN Urea, N-(4-methoxyphenyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-51-1 CAPLUS

CN Urea, N-(2-fluorophenyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-52-2 CAPLUS

CN Urea, N-(2,5-difluorophenyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-53-3 CAPLUS

CN Urea, N-(3,4-difluorophenyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-54-4 CAPLUS

CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-55-5 CAPLUS

CN Urea, N-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 857265-56-6 CAPLUS

CN Urea, N-1,3-benzodioxol-5-yl-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-57-7 CAPLUS

CN Urea, N-(4-fluorophenyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-58-8 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-[3-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-59-9 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-60-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} N & NH-C-NH \\ \hline \\ C & \hline \\ C & NH-CH_2-CH_2-N \\ \hline \\ \\ C & NH-CH_2-N \\ \hline \\ C & NH-C$$

RN 857265-61-3 CAPLUS

CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$CF3$$
 $C=C$
 $NH-C-NH-CH2-CH2-N$
 $NH-CH2-CH2-N$

RN 857265-62-4 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[[3-(4-

morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-63-5 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-64-6 CAPLUS

CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[3-[2-[2-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-65-7 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[4-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c} C = C \\ N \\ NH - C - NH \\ O \\ Me \end{array}$$

RN 857265-68-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[4-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} C & C \\ \hline \\ NH - C - NH \\ \hline \\ O \\ \end{array}$$

RN 857265-69-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[4-[2-[2-[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 857265-70-4 CAPLUS

CN Urea, N-[2-fluoro-5-(trifluoromethyl)phenyl]-N'-[4-[2-[2-[[2-(1-pyrrolidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857265-71-5 CAPLUS

CN Acetamide, N-[5-[2-[3-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]-2-(2-methoxyethoxy)- (CA INDEX NAME)

PAGE 1-B

— СН2— ОМе

RN 857265-72-6 CAPLUS

CN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-pyridinyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 857265-76-0 CAPLUS

CN Urea, N-[2-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-pyridinyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

RN 857265-78-2 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidiny1)ethyny1]-2-thiazoly1]-N'-[2-fluoro-5-(trifluoromethy1)pheny1]- (CA INDEX NAME)

RN 857265-80-6 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 857265-82-8 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

$$C = C$$

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 857265-84-0 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-2-methoxy-(CA INDEX NAME)

$$H_2N$$
 N O MeO $NH-C-CH_2$

RN 857265-85-1 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidiny1)ethynyl]phenyl]- (CA INDEX NAME)

$$\begin{array}{c|c} \mathsf{Ph}-\mathsf{CH_2}-\mathsf{C}-\mathsf{NH} \\ \mathsf{O} \\ \end{array} \qquad \begin{array}{c} \mathsf{C} \\ \mathsf{N} \\ \mathsf{NH_2} \end{array}$$

RN 857265-86-2 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-3-methoxy-(CA INDEX NAME)

$$N$$
 C
 C
 NH
 C
 CH_2
 OMe

RN 857265-87-3 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-3-(trifluoromethy1)- (CA INDEX NAME)

$$N$$
 $C = C$
 $NH - C - CH_2$
 CF_3

RN 857265-88-4 CAPLUS

CN Benzeneacetamide, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)

$$H_2N$$
 N $C = C$ $NH-C-CH_2$ CF_3

RN 857265-89-5 CAPLUS

CN 5-Isoxazoleacetamide, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-3-methyl- (CA INDEX NAME)

$$\begin{array}{c} \text{Me} & \text{N} \\ \text{CH}_2 \\ \text{C} & \text{O} \\ \\ \text{NH} \\ \text{N} & \text{C} & \text{C} \\ \end{array}$$

RN 857265-91-9 CAPLUS

CN Benzeneacetamide, N-[4-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-2-methoxy-(CA INDEX NAME)

RN 857265-92-0 CAPLUS

CN 5-Isoxazoleacetamide, N-[4-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-3-methyl- (CA INDEX NAME)

RN 857265-93-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)- (CA INDEX NAME)

$$C = C$$
 $NH - C - NH$
 Me
 Me

RN 857265-94-2 CAPLUS

CN Urea, N-[6-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-pyrimidinyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 857265-96-4 CAPLUS

CN Urea, N'-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N-[5-(1,1-dimethylethy1)-3-isoxazoly1]-N-methyl- (CA INDEX NAME)

RN 857265-97-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)

RN 857265-98-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-cyclopropyl-1-(1,1-dimethylethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

RN 857265-99-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

$$\begin{array}{c|c} N & O & \\ \hline N & NH - C - NH \\ \hline \end{array}$$

RN 857266-00-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-ethyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)

RN 857266-01-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)

RN 857266-02-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-[4-(1,1-dimethylethyl)-2-thiazolyl]- (CA INDEX NAME)

RN 857266-03-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)

RN 857266-04-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-[5-(trifluoromethy1)-1,3,4-thiadiazol-2-y1]- (CA INDEX NAME)

RN 857266-05-8 CAPLUS

CN Urea, N'-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)

RN 857266-06-9 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-(5-cyclopropyl-1,3,4-thiadiazol-2-y1)- (CA INDEX NAME)

RN 857266-07-0 CAPLUS

CN Urea, N-phenyl-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-09-2 CAPLUS

CN Urea, N-(5-methyl-3-isoxazolyl)-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-10-5 CAPLUS

CN Urea, N-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[4-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)

F₃C
$$N$$
 $NH-C-NH$ $C=C$ N $NH-(CH2)3 $N$$

RN 857266-11-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-12-7 CAPLUS

CN Urea, N-(3-methyl-5-isoxazolyl)-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

Me N O NH C C C NH NH
$$C = C$$

RN 857266-13-8 CAPLUS

CN Urea, N-(2-methoxyphenyl)-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-14-9 CAPLUS

CN Urea, N-(3-fluorophenyl)-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

$$C = C$$
 $NH-C-NH$
 $NH-C-N$

RN 857266-15-0 CAPLUS

CN Urea, N-[3-[2-[4-aminobutyl)amino]-5-pyrimidinyl] ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

NH-C-NH-C-NH-C-NH-(CH₂)
$$_4$$
-NH₂ t-Bu

RN 857266-16-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[2-(1-piperidinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-17-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(1-methylethyl)amino]ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-18-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[2-(2-hydroxyethoxy)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

PAGE 1-A

$$C = C$$
 N
 $NH-CH_2-CH_2-C$
 N

PAGE 1-B

RN 857266-19-4 CAPLUS

CN Urea, N-[3-[2-[4-(dimethylamino)butyl]amino]-5pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA
INDEX NAME)

RN 857266-20-7 CAPLUS

CN Urea, N-[3-[2-[2-[[2-(dimethylamino)-1-methylethyl]amino]-5pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA
INDEX NAME)

RN 857266-21-8 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[1-methyl-2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-22-9 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[1-(2-hydroxyacetyl)-2-pyrrolidinyl]methyl]amino]-5-pyrimidinyl]ethynyl]phenyl](CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 857266-25-2 CAPLUS

CN Urea, N-[3-[2-[[[1-[2-(dimethylamino)acety1]-2-pyrrolidinyl]methyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

Bu-t

RN 857266-26-3 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[2-(1-piperazinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 857266-27-4 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[3-(1-piperazinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-29-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-32-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-33-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-34-3 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-36-5 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-37-6 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-38-7 CAPLUS

CN Urea, N-[3-[2-[2-[[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)

RN 857266-39-8 CAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]-N'-[3-[2-[2-[[2-[(1-methylethyl)amino]ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-40-1 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[[3-(1-piperidinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-42-3 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[[3-(4-morpholinyl)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-43-4 CAPLUS

CN Urea, N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-N'-[3-[2-[2-[[2-(4-morpholinyl)ethyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-44-5 CAPLUS

CN Acetamide, N-[2-[[5-[2-[3-[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy- (CA INDEX NAME)

PAGE 1-A

— сн2- он

RN 857266-45-6 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[[3-[(2-hydroxyethyl)amino]propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

— CH₂— ОН

RN 857266-48-9 CAPLUS

CN Urea, N-[3-[2-[2-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-phenyl- (CA INDEX NAME)

RN 857266-49-0 CAPLUS

CN Urea, N-[3-[2-[2-[[3-(dimethylamino)propyl]amino]-5-pyrimidinyl]ethynyl]phenyl]-N'-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)

RN 857266-50-3 CAPLUS

CN Urea, N'-[3-[2-[3-(dimethylamino)propyl]amino]-5-

pyrimidinyl]ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)

RN 857266-51-4 CAPLUS

CN Urea, N'-[4-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)

RN 857266-53-6 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N-methyl- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 857266-57-0 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-3-pyridinyl]-N'-[5-(1,1-dimethylethyl)-3-isoxazolyl]- (CA INDEX NAME)

RN 857266-61-6 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidiny1)ethyny1]-3-pyridiny1]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)

RN 857266-63-8 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidiny1)ethyny1]-3-pyridiny1]-N'-(3-cyclopropy1-1-methy1-1H-pyrazo1-5-y1)- (CA INDEX NAME)

RN 857266-64-9 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidiny1)ethyny1]-2-thiazoly1]-N'-phenyl- (CA INDEX NAME)

RN 857266-65-0 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidiny1)ethyny1]-2-thiazoly1]-N'-(tetrahydro-2,2-dimethy1-2H-pyran-4-y1)- (CA INDEX NAME)

$$C = C$$
 N_{Me}
 N_{Me}
 N_{Me}

RN 857266-67-2 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-2-thiazolyl]-N'-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 857266-70-7 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidiny1)ethyny1]-2-thiazoly1]-N'-[3-(1,1-dimethylethy1)-1-methyl-1H-pyrazol-5-y1]- (CA INDEX NAME)

RN 857266-74-1 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'-phenyl- (CA INDEX NAME)

RN 857266-78-5 CAPLUS

CN Urea, N-[5-[2-(2-amino-5-pyrimidinyl)ethynyl]-1,3,4-thiadiazol-2-yl]-N'- (tetrahydro-2,2-dimethyl-2H-pyran-4-yl)- (CA INDEX NAME)

RN 857266-82-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

$$\begin{array}{c|c} Me & O & \\ \hline N & NH-C-NH \\ \hline \end{array}$$

RN 857266-84-3 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-[5-(ethylthio)-1,3,4-thiadiazol-2-y1]- (CA INDEX NAME)

RN 857266-86-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-(3-cyclopropy1-1-methy1-1H-pyrazo1-5-y1)- (CA INDEX NAME)

RN 857266-88-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)

RN 857266-90-1 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]pheny1]-N'-[1-(1,1-mino-5-pyrimidiny1)ethyny1]-N'-[1-(1,1-mino-5-pyrimidiny1]-N'-[1-(1,1-mino-5-pyrimidiny1]-N'-[1-(1,

dimethylethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)

RN 857266-93-4 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[1-methyl-3-(1-methylethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

RN 857266-96-7 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)

$$\begin{array}{c|c} N & O & \\ \hline N & NH - C - NH \\ \hline \\ i-Pr & \\ \end{array}$$

RN 857266-99-0 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-(1-ethyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

RN 857267-02-8 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]phenyl]-N'-[1-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

RN 857267-06-2 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidiny1)ethyny1]pheny1]-N'-[3-fluoro-5-(4-methyl-1-piperaziny1)pheny1]- (CA INDEX NAME)

RN 857267-09-5 CAPLUS

CN Urea, N-[3-[2-(2-amino-5-pyrimidinyl)ethynyl]-4-methylphenyl]-N'-[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]- (CA INDEX NAME)

IT 857266-23-0P, N-(5-tert-Butylisoxazol-3-yl)-N'-[3-[[2-

[[(pyrrolidin-2-yl)methyl]amino]pyrimidin-5-yl]ethynyl]phenyl]urea

857266-24-1P, N-(5-tert-Butylisoxazol-3-y1)-N'-[3-[[2-[[[1-(tert-

 $\verb|butoxycarbonyl|| \verb|pyrrolidin-2-y1|| methyl|| amino|| pyrimidin-5-|| methyl|| amino|| amin$

yl]ethynyl]phenyl]urea 857266-52-5P, Phenyl [4-[(2-

aminopyrimidin-5-yl)ethynyl]phenyl]carbamate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as inhibitors of Tie2 receptor tyrosine kinases)

RN 857266-23-0 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N'-[3-[2-[2-[(2-pyrrolidinylmethyl)amino]-5-pyrimidinyl]ethynyl]phenyl]- (CA INDEX NAME)

RN 857266-24-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[2-[3-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]ethynyl]-2-pyrimidinyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 857266-52-5 CAPLUS

CN Carbamic acid, [4-[(2-amino-5-pyrimidinyl)ethynyl]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.83	196.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-2.40

STN INTERNATIONAL LOGOFF AT 08:55:13 ON 08 SEP 2008